All News
EULAR 2021 – Day 1 Report
After the opening ceremonies and keynote speaker there were several enticing sessions and a plenary session full of great research and presentations. Here are a few of the highlights that I saw.
Read Article
EULAR 2021 - Day 1 Podcasts
Check out this compilation of our EULAR 2021 Day 1 broadcasts below.
You can follow the EULAR 2021 RheumNow podcasts on iTunes and Soundclound.com
Listen by Clicking below:
Read Article
Anifrolumab pooled TULIP-1&-2 data on rash and arthritis in SLE more effective in pts with high IFN signals (pts with low IFN may benefit, but they had less rash but more arthritis)- Dr. J Merrill #OP0131 #EULAR2021 @rheumnow
k dao KDAO2011 ( View Tweet)
@KDAO2011 @RheumNow @LupusDocLim @Lupusdoc1 @LupusMD Check this! (top left corner)
#HCQ #Lupus #EULAR2021
Link: https://t.co/RQcWoStJtP https://t.co/96l1FvYDQH
Laurent ARNAUD Lupusreference ( View Tweet)
⬆️prevalence of HCQ retinopathy: Kaiser Permanente 676 pts retrospect study #OP0133
👉6.8% (n=46) had HCQ retinopathy w/ risks:
👉age>80 (OR 3.83)
👉h/o atherosclerosis (OR 2.99),
👉cum. dose >2000 mg (OR 15.8)
👉10-15 yrs use (OR 4.44)
👉>15 yrs (OR 19)
#EULAR2021 @rheumnow https://t.co/QA8HHXdnjL
k dao KDAO2011 ( View Tweet)
News: Featured Abstracts from Industry at EULAR 2021
https://t.co/hIBYUdHTLf https://t.co/LTTJ3WPl7X
Links:
Dr. John Cush RheumNow ( View Tweet)
#EULAR Presentation 3478: Infection risk with surgeries:
⭐️Continue conventional DMARD
⭐️Some risk with biologics, may be confounder and no association with timing of infusions
⭐️Steroids are major risk factor! Esp >10 mg/d
⭐️Recommendations shown
⭐️Address other risks!
@rheumnow https://t.co/Bi02d4p9Mw
Eric Dein ejdein1 ( View Tweet)
COAST-Y 2 yr results: In r- and nr-axSpA, IXE tx led to consistent & sustained long-term improvements in disease activity & QoL. No new safety signals. #EULAR2021 poster #POS0912 @RheumNow https://t.co/W2YoyA4K14 https://t.co/lv0GLU2WTF
Links:
Dr. Rachel Tate uptoTate ( View Tweet)
#EULAR2021: Great talk by Dr. McFarland recapping the evidence for managing fibromyalgia.
➡️Over a 6 month time period, costs were significantly lower for people receiving psychological therapies compared to those receiving usual care as shown by Cabral et al. @RheumNow https://t.co/RAkUSeNESy
Meral K. El Ramahi, MD MeralElRamahiMD ( View Tweet)
Which drug are you most excited about changing future treatments in SLE? #EULAR2021 @RheumNow
Eric Dein ejdein1 ( View Tweet)
What is largest ⬆️ infection risk in RA? steroids, past infection, age, DM? Host factors & Prednisone are Impt. Piling up risk factors is often multiplied! Biggest risk of serious infection and is recurrent serious infection! #EULAR2021 Meet the expert AbbVie session @RheumNow https://t.co/6m0OfsNF1W
Janet Pope Janetbirdope ( View Tweet)
Q-DAPSA (DAPSA + CRP), validated as a clinical measure of PsA disease activity in both practice & research from 5 centers in Berlin, 104 PsA pts. Let's get more studies to better understand the power of this measure. Poster #POS1069 #EULAR2021 @RheumNow https://t.co/X4UWGwH5i5 https://t.co/J7EpOjTjhe
Dr. Rachel Tate uptoTate ( View Tweet)
Dr Lukas presents data showing possibility of tapering a range of TNF in AxSpA patients in remission 162/184 (88.0%) LDA in progressive spacing group vs 173/189 (91.5%) in continued at 1 year.@RheumNow #EULAR2021 Abstr#0138
Richard Conway RichardPAConway ( View Tweet)
Honoured to be part of the irAE session at #EULAR2021, with some great talks (and then also mine), including:
- Anne Bass @lovetolearn27 @HSpecialSurgery on irAE mechanisms
- Maria Suarez-Almazor @MDAndersonNews on irAEs in the clinic
Well worth tuning into! @RheumNow https://t.co/MN1IcLKv6u
David Liew drdavidliew ( View Tweet)
Abst#OP0137 at #EULAR2021:
➡️TNFi use for at least 1 year decreased radiographic sacroiliitis progression in early AxSpA in this ten year multicenter study of the German Spondyloarthritis Inception cohort (GESPIC) .
➡️This effect becomes evident 2-4 years after tx.
@RheumNow https://t.co/GNnYqYmxhl
Meral K. El Ramahi, MD MeralElRamahiMD ( View Tweet)
SPACING trial: possible to taper TNFi in AxSpA pts in LDA
⭐️Tapering of TNFi in axSpA resulted in 88% BASDAI<4 compared to 91.5% in unchanged group
⭐️adalimumab spaced out to q35 days
Abs#OP0138
#EULAR2021 @RheumNow
Robert B Chao, MD doctorRBC ( View Tweet)
PROs in Spa and PSA: Dr. Rachel Tate ( @uptoTate)
https://t.co/sUXTXDXrFh
Links:
Dr. John Cush RheumNow ( View Tweet)
Based on the data, what would you do in a new SLE patient w/LN class IV who is already on a background of GC's+HCQ? @rheumnow @kidneydoc101 @Lupusreference
k dao KDAO2011 ( View Tweet)
The case for starting combo Rx for LN (rather than sequential Rx):
👉Aurora trial: voclosporin + MMF (vs. MMF only) prompt efficacy on proteinuria across all ethnic subgroups, twice more complete renal response , no major safety signals. slide 1/ #EULAR2021 @rheumnow https://t.co/TA5i9ITuL7
k dao KDAO2011 ( View Tweet)
#Digital #rheumatology in the era of #COVID-19: evidently increasing inclination of patients and physicians to use digital health apps for recording data- as informed by a national survey by @JK77775 and colleagues #EULAR2021 @ARD_BMJ https://t.co/Uo60qZurhG
Latika LatikaGupta_ ( View Tweet)